RIPK1 and central nervous system cancer: To test the relevance of our data, we assessed the ability of ZFP36 to control RIP1 stability in human glioma neural stem cell lines (GNS), as this population shows resistance to standard therapy and is believed to mediate tumor recurrence [13].